Lundbeck to cull 200 staffers in cost-cutting drive

Lundbeck is laying off about 200 people as it targets a top-to-bottom efficiency campaign aimed at clinical trials, administration and supply chain work in a cost-savings drive. The pharma company expects to save about a half billion Danish kroner annually in the move. "Lundbeck remains fully committed to our long-term strategy and over the years we have taken decisive steps in order to improve our organizational efficiencies and our ability to succeed in a changing environment," said Anders Götzsche, EVP and CFO at Lundbeck. "We are very aware that these initiatives affect many employees and we will strive to mitigate any negative effects these might have." Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.